Sanofi Ends Trial Of STAT6 Degrader, Wiping Out Nurix's Milestone And Royalty Prospects On It
Nurix remains eligible for payments on other licensed programs in its Sanofi collaboration, which Sanofi may develop at its discretion.
Nurix Therapeutics, which develops drugs designed to remove disease-causing proteins, said Tuesday that partner Sanofi is ending its first-in-human trial of SAR448272, an oral STAT6 degrader, and terminating the program. Nurix no longer expects the milestone payments or royalties it was eligible for on that drug.
A partnered drug is shelved
Sanofi told Nurix it will discontinue the Phase 1 trial, an early-stage study in people, and shut down the SAR448272 program, according to the company's 8-K.
Nurix said it does not expect any of the future development, regulatory or commercial milestone payments, or royalties, it could have earned on SAR448272 under the Sanofi collaboration.
What remains in the Sanofi deal
Nurix stays eligible for milestones and royalties on its other previously announced licensed programs under the Sanofi collaboration. Those depend on Sanofi choosing, at its discretion, to develop them further into clinical candidates.
The company flagged two risks: Sanofi may decide not to advance the other licensed programs, and collaborators may discontinue or delay partnered programs.
A business built on partners
Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and inflammatory diseases. According to its annual report for the fiscal year ended November 30, 2025, its own pipeline has three investigational candidates in clinical studies: bexobrutideg and zelebrudomide, which degrade a protein called BTK, and NX-1607, which inhibits a protein called CBL-B.
Its revenue comes from collaborations with Gilead Sciences, Sanofi and Pfizer, which use its machine-learning-driven discovery platform. As of November 30, 2025, collaborators had paid it $482.0 million, and it was eligible for up to $6.1 billion in future fees and milestones, plus royalties on future product sales.
Whether Sanofi moves any of the remaining licensed programs into clinical candidates now determines what Nurix can still earn under the collaboration.
Sources
- 8-K Filing — Nurix Therapeutics, Inc. (NRIX) — SEC EDGAR
